Ontology highlight
ABSTRACT:
SUBMITTER: Jaglowski SM
PROVIDER: S-EPMC4536539 | biostudies-literature | 2015 Aug
REPOSITORIES: biostudies-literature
Jaglowski Samantha M SM Jones Jeffrey A JA Nagar Veena V Flynn Joseph M JM Andritsos Leslie A LA Maddocks Kami J KJ Woyach Jennifer A JA Blum Kristie A KA Grever Michael R MR Smucker Kelly K Ruppert Amy S AS Heerema Nyla A NA Lozanski Gerard G Stefanos Mona M Munneke Brian B West Jamie-Sue JS Neuenburg Jutta K JK James Danelle F DF Hall Nathan N Johnson Amy J AJ Byrd John C JC
Blood 20150626 7
Ibrutinib represents a therapeutic advance in chronic lymphocytic leukemia (CLL) but as monotherapy produces few complete remissions in previously treated patients. Anti-CD20 antibodies have improved response and progression-free survival (PFS) when combined with chemotherapy. We evaluated the safety and activity of adding ofatumumab to ibrutinib in 3 different administration sequences. Patients with CLL/small lymphocytic lymphoma (SLL), prolymphocytic leukemia, or Richter's transformation who f ...[more]